Harnessing Type 2 Immunity to Revitalize Exhausted CD8+ T Cells and Enhance Cancer Immunotherapy
Type 2 cytokine Fc-IL-4 can directly act on CD8+ T cells to enrich and reinvigorate terminally exhausted CD8+ T cells, thereby enhancing the efficacy of type 1 immunity-based cancer immunotherapies.